Anti-CD19 CAR T cells expanded in 1B2H showed potent in vivo anti-tumor activity with improved T cell persistence compared to CAR T cells expanded in X-VIVO15, even though CAR T cells maintained in X-VIVO15 contained slightly higher percentages of T cells with a less differentiated phenotype at the end of ex vivo expansion. Here, CD19 is linked to neoplasm.